972 results on '"Röllig, Christoph"'
Search Results
2. How to customize common data models for rare diseases: an OMOP-based implementation and lessons learned
3. Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligence
4. Prognostic impact of CEBPA mutational subgroups in adult AML
5. Biallelic TET2 mutation sensitizes to 5’-azacitidine in acute myeloid leukemia
6. Ex vivo drug response profiling for response and outcome prediction in hematologic malignancies: the prospective non-interventional SMARTrial
7. Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia
8. Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification
9. Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: a real-world registry experience
10. Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
11. Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial
12. Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD
13. UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome
14. Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles
15. Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome
16. Isocitrate dehydrogenase 1 mutation drives leukemogenesis by PDGFRA activation due to insulator disruption in acute myeloid leukemia (AML)
17. Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy
18. Large case-control study indicates no association of KIR genotype and risk of developing acute myeloid leukemia
19. Retained functional normal and preleukemic HSCs at diagnosis are associated with good prognosis in DNMT3AmutNPM1mut AMLs
20. Overlapping features of therapy-related and de novo NPM1-mutated AML
21. Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia
22. Treatment of Newly Diagnosed AML in Fit Patients
23. Mini-consolidations or intermediate-dose cytarabine (IDAC) for the post-remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries.
24. Gemtuzumab ozogamicin plus midostaurin in combination with standard ‘7 + 3’ induction therapy in newly diagnosed AML: Results from the SAL‐MODULE phase I study
25. Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries
26. Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1
27. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
28. Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial
29. Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse
30. Deep sequencing in CD34+ cells from peripheral blood enables sensitive detection of measurable residual disease in AML
31. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial
32. Deep learning detects acute myeloid leukemia and predicts NPM1 mutation status from bone marrow smears
33. Half-dose glucarpidase as efficient rescue for toxic methotrexate levels in patients with acute kidney injury
34. Deep learning identifies Acute Promyelocytic Leukemia in bone marrow smears
35. Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation
36. Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia
37. Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations
38. Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study
39. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome
40. A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries
41. No impact of time from diagnosis to treatment on survival in newly diagnosed AML treated with venetoclax-based regimens
42. Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial
43. Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia
44. miR-10a as a therapeutic target and predictive biomarker for MDM2 inhibition in acute myeloid leukemia
45. Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib
46. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study
47. MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1–2a trial
48. Radioimmunotherapy in Combination with Reduced-Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Advanced Multiple Myeloma
49. Improving long-term outcomes with intensive induction chemotherapy for patients with AML
50. How to customize Common Data Models for rare diseases: an OMOP-based implementation and lessons learned
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.